New Year’s press conference, new blockbuster drug creation, etc.
Loss Guarantee System, President’s Direct Control Tower Proposal for’Glance’
“It is urgent to strengthen the organization of industrial policies within the Ministry of Health and Welfare”
Won Hee-mok, chairman of the Korea Pharmaceutical Bio Association, said that this year will be a turning point in the establishment of pharmaceutical sovereignty based on the results of the development of COVID-19 treatment and vaccine.
Chairman Won Hee-mok said at the New Year’s online press conference on the 27th, “The Corona 19 pandemic is reminding us of the importance of a social safety net that protects the health and lives of the people. The solution to end the national crisis is the development of treatments and vaccines.” .
“Many domestic pharmaceutical bio companies are also making every effort to develop treatments and vaccines. We will continue to responsibly carry out the development of treatments and vaccines, which will be the responsibility of our industry, and make it a turning point in establishing pharmaceutical sovereignty.” Added.
This year, the Korea Pharmaceutical Bio Association is planning to implement four major tasks such as ▲ strengthening health and security ▲ creating new blockbuster drugs ▲ accelerating global advancement ▲ industrial environment innovation. Chairman Hee-mok Won’s plan is to protect the people from Corona 19 and put all of his capabilities into opening an era of success for K-PHARM on the global stage.
Chairman Hee-mok Won said, “We plan to promote the expansion of the scope and scale of R&D support at the national level to accelerate the development of COVID-19 treatments and vaccines in relation to’reinforcement of health and security.’ He emphasized that, by strengthening communication between the Korea Centers for Disease Control and Prevention, an infectious disease control tower, and the industry, difficulties in the field will be resolved.”
In particular, the association plans to request a support plan such as a loss guarantee system that allows drugs under development to see light after the pandemic is over.
Chairman Hee-mok Won said, “We will focus on solving the uncertainty that is an obstacle to corporate activities such as investment and R&D. We will create an environment that allows us to have a relationship.”
It is also planning to strengthen its ability to develop new blockbusters through open innovation.
Chairman Hee-mok Won said, “Yoohan Corporation, a subsidiary of the bio company Oscotech, introduced a candidate for lung cancer treatment that was in the pre-clinical stage, and then conducted clinical trials.” I received a new domestic drug). This is a representative example of open innovation.”
“It’s not just the case of Yuhan Yanghan. The reality is that global big pharmas are also searching for promising pipelines in bio-startups, ventures, and third countries. “Open innovation is the trend.” “We will expand various strategic alliances through extensive cooperation with Korean companies, global companies, and medical institutions, including the Korea Innovative Drug Consortium (KIMCo), in which many member companies participated.”
The innovation base to accelerate global advancement will also be put into operation. Chairman Won Hee-mok said, “New attempts and constant challenges are the key to creating future value. We have established the’Hankuk Pharmaceutical Bio Innovation Center’ (tentatively called KPBIC) in Boston, USA so that companies can boldly jump into the global market and are operating in earnest. We are also promoting the installation of a second KPBIC in EU base countries.”
According to the Pharmaceutical Bio Association, KPBIC will receive administrative support from the Korean Consulate in Boston and business support from the Boston Branch of the Health Industry Promotion Agency. It plans to develop into a global innovation base for the pharmaceutical bio industry through an advisory function composed of local experts.
Chairman Hee-mok Won said, “Currently, a practical consulting program is in operation in which protagonists who have experienced major clinical research, business development, legal, international patent applications and disputes in the global new drug development ecosystem participate as advisors. It will be more active in the future.”
As part of innovation in the industrial environment, the pharmaceutical market is expected to strengthen transparency.
Chairman Hee-mok Won said, “Ethical management is an imperative task for the industry and an essential condition to increase international competitiveness.” In order to increase market transparency, we plan to promote the MR qualification certification system as a nationally recognized certificate and promote CSO training. In order to cut off the rebate culture, it will promote the’MR qualification certification system’ and’CSO training’ for sales personnel of pharmaceutical companies through two-track.
Also, “Since the introduction of ISO 37001 (Anti-Corruption Management System) in 2017, 63 companies have been certified. As a result of the analysis of the introduction effect by the Transparency Korea, the integrity awareness of the introduced companies was relatively excellent. We will continue to internalize corporate ethical management through continuous education and self-assessment system.”
Meanwhile, Chairman Won Hee-mok proposed the’installation of a control tower directly under the president’. He said, “It is desperate to install a control tower under the direct control of the President. In this case, in response to global environmental changes, we establish the vision, goals, and mid- to long-term strategies of the domestic health industry, and integrate the development and implementation of policies on a full-cycle from basic research to completion of clinical trials I can manage it.”
He added, “Because the biohealth industry is a social safety net that is directly connected to the health of the people and a growth engine that will lead the future national economy, a rational harmony between the regulatory policy and the fostering policy is needed.” It is also necessary to strengthen the policy organization and expand its role.”
Copyright © Farm News Unauthorized reproduction and redistribution prohibited